News by Subject Social & Behavior

Spain is among the five countries in the world with the highest levels of social acceptance of LGBTIQ+ people and rights, and was the third country in the world to legalize same-sex marriages, in 2005. In 2019, 3.1% of marriages were between same-sex couples (INE 2020). In this context, it would seem consistent that sexual orientation should not determine wage inequalities. But is this really so? What is the relationship between sexual orientation and wages?

A study at the University of Chicago Medicine found U.S. women experienced increased incidence of health-related socioeconomic risks (HRSRs), such as food insecurity and interpersonal violence, early in the COVID-19 pandemic.

Women who suffer from vision, hearing or dual sensory loss are more than twice as likely to report depression and anxiety as men who experience the same issues, according to a new study by Anglia Ruskin University (ARU).

The health of women aged 65 and over appears to be related, in addition to their own socioeconomic characteristics, with that of their partners, as a result of traditional gender norms. This is one of the main conclusions of research led by Jordi Gumà, a researcher at UPF, conducted in conjunction with Jeroen Spijker, a Ramon y Cajal I3 researcher at Autonomous University of Barcelona, focusing on the case of Spain.

American adults 65 years old and older have better vision than that age group did nearly a decade ago, according to a recent study published in the journal Ophthalmic Epidemiology.

A new University of Houston report offers interventions for graduate schools to become more inclusive of transgender and nonbinary students, who can suffer from a toxic environment in an atmosphere that is already a pressure cooker.

Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines.

An independent analysis of the medical trials which formed the final basis of approval by the US Food and Drug Administration (FDA) strongly suggests the drug bremelanotide has very limited effectiveness as a treatment for hypoactive sexual desire disorder (HSDD) in women, and that trial participants preferred a placebo.